EGFR and non-small cell lung carcinoma: Gefitinib and erlotinib are oral EGFR-TKIs and have been approved in Asia for advanced NSCLC patients who have failed prior chemotherapy, or as first-line therapy for those with EGFR activating mutations [7–10].